Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Discovery
Sponsor : Ipsen
Deal Size : $1,020.0 million
Deal Type : Collaboration
ipsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
Details : Under the agreement, Ipsen will receive exclusive options to license SNA-based therapeutics arising from two collaboration programs for Huntington’s disease and Angelman syndrome.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $20.0 million
February 08, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery
Sponsor : Ipsen
Deal Size : $1,020.0 million
Deal Type : Collaboration